Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.041 | 1 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0242 | 0.2852 | 0.5 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.0242 | 0.2852 | 0.5 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.041 | 1 | 0.5 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.041 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0403 | 0.9706 | 0.9604 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0403 | 0.9706 | 0.9706 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.0403 | 0.9706 | 0.9706 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.041 | 1 | 1 |
Onchocerca volvulus | 0.041 | 1 | 0.5 | |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0403 | 0.9706 | 0.9706 |
Loa Loa (eye worm) | hypothetical protein | 0.041 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.041 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0403 | 0.9706 | 0.9706 |
Giardia lamblia | Hypothetical protein | 0.0242 | 0.2852 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.041 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0242 | 0.2852 | 0.5 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.0242 | 0.2852 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
MIC (functional) | > 512 ug ml-1 | Antimicrobial activity against Candida albicans PTCC 5027 after 24 hr by Alamar blue assay | ChEMBL. | No reference |
MIC (functional) | > 512 ug ml-1 | Antimicrobial activity against Escherichia coli PTCC 1338 after 24 hr by Alamar blue assay | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.